Physician profile
Derrick M Brown
NPI 1942270848
$17,116.82
in general payments reported to CMS, 2019-2025
53 companies · $2,636 in 2025
The $2,636 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,686 · 2020: $1,786 · 2021: $1,876 · 2022: $2,723 · 2023: $2,624 · 2024: $2,786 · 2025: $2,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,045.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,554.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,837.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,461.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,053.55 | 2019-2024 | Xifaxan, Cycloset |
| Pfizer INC. | $989.88 | 2019-2025 | |
| Abbott Laboratories | $977.49 | 2020-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $955.05 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $937.45 | 2019-2025 | Jardiance |
| Abbvie INC. | $895.09 | 2019-2025 | Qulipta, Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $718.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $594.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $501.03 | 2019-2023 | Belsomra, Steglatro, Januvia |
| Bayer Healthcare Pharmaceuticals INC. | $433.29 | 2022-2025 | |
| Amgen INC. | $428.41 | 2020-2025 | Repatha, Otezla, Krystexxa |
| Amarin Pharma, INC. | $372.67 | 2019-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.